NCT07067385View on ClinicalTrials.gov

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant TherapyGastrointestinal Tumors
Interventions
BIOLOGICAL

Neoantigen Personalized Cancer Vaccine

Cohort 1: subjects will receive neoantigen tumor vaccine combination with Sintilimab. Cohort 2: subjects will receive neoantigen tumor vaccine combination with Sintilimab and chemotherapy .

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
collaborator

deepGeneAI

UNKNOWN

collaborator

Bio-X Institutes, Shanghai Jiao Tong University

UNKNOWN

lead

Ruijin Hospital

OTHER